• -11%
  • New
Anadrol Injectable - Oxymetholone 100mg | Dragon Pharma
search
  • Anadrol Injectable - Oxymetholone 100mg | Dragon Pharma

Anadrol Inj

$75.00
$66.75 Save 11%

Oxymetholone

Anadrol Injβ€’50 mg/ml
Class Injectable 17Ξ±-Alkyl AAS
Concentration 50 mg/ml
Half-Life ~8–16 hours
Anabolic Ratio 320
Carrier MCT Oil
Form Injection, 10ml

Quantity

  Security policy

(edit with the Customer Reassurance module)

  Delivery policy

(edit with the Customer Reassurance module)

  Return policy

(edit with the Customer Reassurance module)

Anadrol Injectable β€” Oxymetholone 50mg/ml by Dragon Pharma

Anadrol Injectable is Dragon Pharma's intramuscular formulation of Oxymetholone at 50mg/ml β€” the same active compound as oral Anadrol delivered via injection to bypass the first-pass hepatic exposure responsible for oral Oxymetholone's significant liver toxicity. Oxymetholone is unique among 17-alpha-alkylated AAS in having both an established oral pharmaceutical form and a viable injectable format, with the injectable route specifically preserving the compound's extraordinary anabolic potency while meaningfully reducing the concentrated first-pass hepatotoxicity of the oral tablet.

Also searched as: Injectable Anadrol, Oxymetholone injection, Anadrol Inj 50mg, injectable Oxy, Dragon Pharma Anadrol.

Why Injectable Oxymetholone β€” The Hepatotoxicity Bypass

The rationale for injectable Oxymetholone follows the same logic as injectable Superdrol β€” but with an important distinction:

  • Oral Oxymetholone (Anadrol tablets) must pass through the liver entirely during first-pass metabolism β€” the 17-alpha-alkyl group protects the compound from hepatic degradation, but this also means concentrated, extended exposure of liver tissue to the compound during each oral dose
  • Injectable Oxymetholone enters systemic circulation directly via intramuscular absorption, bypassing the portal circulation entirely. The compound reaches the liver only via systemic blood flow β€” at a far lower concentration than first-pass oral delivery
  • The practical result: injectable Oxymetholone produces substantially lower liver enzyme (ALT/AST) elevation than oral Oxymetholone at equivalent doses β€” hepatotoxicity is meaningfully reduced, though not eliminated (the compound still reaches the liver systemically)
  • The important distinction from oral-only AAS like Dianabol: Oxymetholone has clinical injectable precedent β€” pharmaceutical injectable Oxymetholone formulations have existed in medical literature, unlike many AAS where the injectable form is purely underground production

Oxymetholone's Unique Estrogen Paradox

This is one of the most pharmacologically interesting and most consistently misunderstood aspects of Anadrol:

  • Oxymetholone does not aromatise to estradiol β€” the chemical structure prevents aromatase from converting it to an estrogenic metabolite. By this logic, it should produce no estrogenic side effects
  • In practice, Oxymetholone produces pronounced estrogenic effects β€” significant water retention, gynecomastia risk and bloating that rival or exceed compounds that aromatise heavily like Dianabol
  • The proposed mechanism: Oxymetholone or its metabolites may act as partial agonists at the estrogen receptor directly β€” activating ERΞ± without going through aromatase conversion. This would explain estrogenic effects without measurable estrogen elevation
  • The critical practical consequence: standard aromatase inhibitors (Anastrozole, Exemestane, Letrozole) may provide limited protection against Anadrol's estrogenic side effects β€” they block aromatase, but if the estrogenic effect is from direct ER activation rather than aromatisation, the AI does not address the root cause
  • SERMs (Nolvadex, Raloxifene) are more effective than AIs against Anadrol-induced gynecomastia β€” because SERMs block the estrogen receptor directly, they prevent ER activation regardless of whether the agonist arrives via aromatisation or direct ER binding

Injectable vs Oral Oxymetholone β€” The Comparison

Parameter Anadrol Injectable (50mg/ml) Anadrol Oral (50mg tab)
Route Intramuscular injection Oral tablet
First-pass hepatic exposure Bypassed entirely Full first-pass β€” concentrated hepatic exposure
Hepatotoxicity Significantly reduced vs oral Significant β€” primary limitation of oral Anadrol
Anabolic potency Identical compound β€” same potency Identical
Estrogenic effects Same β€” direct ER mechanism, not aromatase-dependent Same
Dose flexibility Volume-based (0.5ml = 25mg) Tablet-based (50mg increments)
Cycle length 4–6 weeks (reduced hepatic burden) 3–4 weeks maximum

Effects and Benefits

  • Rapid and significant mass and strength gains β€” Oxymetholone's anabolic ratio of 320 and extreme volumising effects produce the most dramatic weight and strength increases of any oral/injectable AAS in this range
  • Volumising effect β€” significant cell volumisation from osmotic shifts; substantial increase in training "pump"
  • Reduced hepatotoxicity versus oral tablet β€” the primary advantage of the injectable format
  • Longer viable cycle length β€” 4-6 weeks versus oral's 3-4 week maximum
  • Erythropoietic effect β€” Oxymetholone stimulates red blood cell production; historically prescribed for aplastic anaemia

Dosage and Administration

Protocol Daily Dose Volume Cycle Length
Conservative (first injectable Oxy cycle) 50 mg/day (1ml) 1ml daily IM 4–6 weeks
Standard 100 mg/day (2ml) 2ml daily IM 4–5 weeks

Daily injection maintains stable blood levels from the ~8-16 hour half-life. Rotate injection sites β€” daily IM injection requires strict rotation between gluteal, vastus lateralis and deltoid sites. Use Nolvadex or Raloxifene rather than AI for gynecomastia prevention β€” the direct ER mechanism is not adequately managed by aromatase inhibitors alone. Liver monitoring remains advisable even with injectable route.

Comments (0)
No customer reviews for the moment.